Please login to the form below

Not currently logged in
Email:
Password:

Levest COC promises NHS cost savings

Combined oral contraception, Levest, has won an NHS contract as the preferred drug of its type for hospitals in England

In addition to being listed by the majority of retail pharmacy wholesalers and multiples, Morningside Healthcare's combined oral contraception (COC), Levest, has won an NHS contract as the preferred drug of its type for hospitals in England.

Levest contains levenogesterel 150μg and ethinylestradiol 30μg and costs £2.55 per 63 tablets, or the equivalent of just £0.85 per cycle. This makes it 10 per cent cheaper than competitor, Microgynon 30 (ethinylestradiol and levonorgestrel), which costs £2.82 per 63 tablet, or £0.94 per cycle.

With an estimated one million women in England currently prescribed Microgynon, the potential cost savings for the NHS in England are in excess of £1m a year.

Dr Al-Azzawi, consultant gynaecologist, comments: "The clinical data demonstrates that Levest is bioequivalent to Microgynon 30 and can be prescribed in place of it without any loss of contraceptive efficacy."

5th May 2010

From: Healthcare

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics